endpts.com Open in urlscan Pro
143.204.215.22  Public Scan

Form analysis
1 forms found in the DOM

https://endpts.com/

<form action="https://endpts.com/">
  <input type="text" name="s" placeholder="Search">
  <button class="epn_ux_button epn_white epn_search_submit_button"></button>
</form>

Text Content

 * Channels
   * All News
   * In Focus
   * Special
   * AI
   * Bioregnum
   * Biotech Voices
   * Cell/Gene Tx
   * China
   * Coronavirus
   * Deals
   * Diagnostics
   * Discovery
   * FDA+
   * Financing
   * Law
   * Letters to the Editor
   * Manufacturing
   * Marketing
   * Opinion
   * Outsourcing
   * Peer Review
   * People
   * Pharma
   * R&D
   * Startups
   * Weekly
 * Webinars
 * Biopharma Jobs
 * More
   * Work at Endpoints
   * Letter to Editors
   * IPO Tracker
   * Webinars
   * Events
   * Sponsored Posts
   * Advertise
   * Privacy Policy
   * Endpoints Merch
   * About Us
   * Help


 * SIGN UP
 * LOG IN



July 19, 2023 07:32 AM EDTUpdated 09:00 AM
R&D


AMARIN LAYS OFF US SALES­FORCE, NAMES NEW CEO IN SHAKE­UP


AMBER TONG

SENIOR EDITOR

The new crew in charge at Amarin has out­lined their plans to turn things around
— and it in­volves a sweep­ing re­org.

Amarin will cut all US sales po­si­tions and 30% of non-sales roles, while
re­tain­ing a lim­it­ed team to sup­port Vas­cepa, its phar­ma­ceu­ti­cal-grade
fish oil de­riv­a­tive. In­stead, it will fo­cus on reach­ing more pa­tients in
Eu­rope (where the drug is mar­ket­ed as Vazkepa) as well as oth­er
in­ter­na­tion­al mar­kets. Patrick Holt is step­ping in as pres­i­dent and CEO,
re­plac­ing in­ter­im chief Aaron Berg, who will stay on as EVP and pres­i­dent
in the US.


TO READ ENDPOINTS NEWS BECOME A FREE SUBSCRIBER

Unlock this article instantly, along with access to limited free monthly
articles and our suite of newsletters

SIGN UP LOG IN


MORE LIKE THIS

 * Vir’s GSK-al­lied flu pre­ven­tion an­ti­body fails PhII, sink­ing shares and
   late-stage hope July 20, 2023
 * An­titrust en­forcers roll out draft guide­lines amid crack­down on
   phar­ma­ceu­ti­cal merg­ers July 19, 2023
 * Af­ter year­long de­lay, FDA com­pletes in­spec­tion for No­var­tis,
   BeiGene's an­ti-PD-1 drug from Chi­na July 18, 2023


TRENDING NOW


SPE­CIAL RE­PORT 2023: MEET 20 WOMEN RE­SHAP­ING BIO­PHAR­MA


BIOTECH’S OP­TI­MISM IS RE­TURN­ING AMID SIGNS OF A BET­TER SEC­OND HALF AND A
BRIGHTER 2024


A SMALL SWISS BIOTECH TACK­LES A HUGE GLOB­AL HEALTH IS­SUE WITH A HAND­OFF FROM
GSK. BUT CAN IT MAKE ANY MON­EY FROM IT?


AFFI­NI-T TO CLOSE SEAT­TLE LAB AS IT CON­CEN­TRATES IN BOSTON, PREPS TWO IND
FIL­INGS IN NEXT TWO MONTHS


SEC FINES FOR­MER MER­CK EX­EC OVER IN­SID­ER TRAD­ING AL­LE­GA­TIONS


STAN­FORD PRES­I­DENT RE­SIGNS FOL­LOW­ING SCI­EN­TIF­IC MIS­CON­DUCT
IN­VES­TI­GA­TION

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas




LATEST

 * All News
 * Special
 * In Focus
   


CHANNELS

 * AI
 * Bioregnum
 * Biotech Voices
 * Cell/Gene Tx
 * China
 * Coronavirus
 * Deals
 * Diagnostics
 * Discovery
 * FDA+
 * Financing
 * Law
 * Letters to the Editor
 * Manufacturing
 * Marketing
 * Opinion
 * Outsourcing
 * Peer Review
 * People
 * Pharma
 * R&D
 * Startups
 * Weekly


MORE

 * Work at Endpoints
 * Letter to Editors
 * IPO Tracker
 * Events
 * Webinars
 * Sponsored Posts
 * Advertise
 * Endpoints Merch
 * About Us
 * Help


WORK IN BIOTECH

 * Endpoints Careers

© Endpoints News 2023

 * Help
 * Advertise
 * Privacy Policy
 * Business Model




LOG IN TO YOUR ACCOUNT


E-MAIL




PASSWORD


Change my password Get a magic email link
LOG IN


REQUEST MAGIC LINK

If you're already an Endpoints subscriber, enter your email below for a magic
link that lets you log in quickly without using a password. Please note the
magic link is one-time use only and expires after 24 hours.


EMAIL


BACK
REQUEST


RESET PASSWORD

We'll e-mail you a link to set a new password. Please note this link is one-time
use only and is valid for only 24 hours.


EMAIL


BACK
RESET


ABOUT YOU







SUBSCRIPTIONS

ENDPOINTS NEWS Daily at 11:30 AM ET



EARLY EDITION Daily at 7:15 AM ET



ENDPOINTS PHARMA Daily at 2 PM ET



BREAKING NEWS ALERTS 2-3 times a week



ENDPOINTS MARKETING RX Tue at 2 PM ET



ENDPOINTS FDA+ Wed at 2 PM ET



ENDPOINTS MANUFACTURING Thu at 2 PM ET



ENDPOINTS WEEKLY Sat at 6 AM ET


INSTANT SIGN UP